Loading news...
SENS highlights strong one-year real-world data for Eversense 365, reinforcing adherence, glucose control and long-term adoption potential.
Senseonics Holdings, Inc. Common Stock (NASDAQ: SENS - Get Free Report) has been assigned an average rating of "Moderate Buy" from the seven brokerages that are covering the stock, MarketBeat Ratings reports. One analyst has rated the stock with a sell rating, one has given a hold rating, three have assigned a buy rating and two
New data shows positive real-world impact of the world's first and only one-year CGM, with a full year of strong patient adherence, glucometrics and hypoglycemic outcomes
The consensus price target hints at a 124.5% upside potential for Senseonics (SENS). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.
Senseonics Holdings, Inc. (SENS) Q4 2025 Earnings Call Transcript
Senseonics Holdings (SENS) came out with a quarterly loss of $0.46 per share versus the Zacks Consensus Estimate of a loss of $0.43. This compares to a loss of $0.4 per share a year ago.
Generated Q4 revenue of $14.3 million, an increase of 72% year-over-year Received CE Mark approval for commercialization of Eversense 365 in Europe Launched first Eversense 365 AID system integration, with twiist in the US GERMANTOWN, Md., March 02, 2026 (GLOBE NEWSWIRE) -- Senseonics Holdings, Inc. (NASDAQ: SENS) a medical technology company focused on the development, manufacturing and commercialization of long-term, implantable continuous glucose monitoring (CGM) systems for people with diabetes, today announced fourth quarter 2025 financial results and provided a business update.
Senseonics rolls out Eversense 365 integrated with Sequel's twiist AID system, aiming to boost CGM adoption with its year-long wear advantage.
The integrated system is now being used in real-world care settings and is widely available for people with type 1 diabetes The integrated system is now being used in real-world care settings and is widely available for people with type 1 diabetes
The integrated system is now being used in real-world care settings and is widely available for people with type 1 diabetes The integrated system is now being used in real-world care settings and is widely available for people with type 1 diabetes
Shares of Senseonics Holdings, Inc. (NYSE: SENS - Get Free Report) have been assigned a consensus rating of "Buy" from the six ratings firms that are presently covering the stock, MarketBeat Ratings reports. One investment analyst has rated the stock with a hold recommendation, three have assigned a buy recommendation and two have issued a strong
Senseonics (SENS) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
Senseonics (SENS) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near term.
Senseonics stock jumps after Eversense 365 wins CE Mark, expanding Europe access for its one-year CGM and strengthening the long-term growth outlook.
GERMANTOWN, Md., Jan. 29, 2026 (GLOBE NEWSWIRE) -- Senseonics Holdings, Inc. (NASDAQ: SENS) a medical technology company focused on the development and manufacturing of long-term, implantable continuous glucose monitoring (CGM) systems for people with diabetes, today announced CE Mark approval for the Eversense® 365 CGM system.
Senseonics shares gain after Eversense 365 became the first one-year implantable CGM integrated with an automated insulin delivery system.
twiist™ becomes the first AID system compatible with Senseonics Eversense® 365 one-year CGM twiist™ becomes the first AID system compatible with Senseonics Eversense® 365 one-year CGM
Senseonics Holdings, Inc. (NYSE: SENS - Get Free Report) has been given an average recommendation of "Buy" by the six analysts that are covering the company, MarketBeat.com reports. One equities research analyst has rated the stock with a hold rating, three have issued a buy rating and two have issued a strong buy rating on the
HBK Sorce Advisory LLC bought a new position in shares of Senseonics Holdings, Inc. (NYSE: SENS) during the undefined quarter, according to the company in its most recent Form 13F filing with the SEC. The institutional investor bought 83,398 shares of the company's stock, valued at approximately $39,000. Several other institutional investors also
Senseonics Holdings earns a buy rating as Eversense 365 drives potential product-market fit and margin expansion. SENS's integration of Ascensia's commercial team and DTC investments is expected to boost revenue and gross margins above 50%. Q3 revenue grew 90% YoY, with a 42.8% gross margin and 55% YoY revenue growth guided for 2025.